Company profile
SCYNEXIS INC
NASDAQ:SCYXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBREXAFUNGERP | phase3 | — | 13 | completed, terminated |
| SCY-635 | phase2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05178862 | phase3 | terminated | 2022-08-03 | 2025-11-07 | Scynexis, Inc. | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole |
| NCT04307082 | phase1 | completed | 2019-12-05 | 2020-05-29 | Scynexis, Inc. | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects |
| NCT05668429 | phase1 | completed | 2022-12-14 | 2023-01-28 | Scynexis, Inc. | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects |
| NCT03253094 | phase2 | completed | 2017-08-01 | 2018-05-04 | Scynexis, Inc. | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis |
| NCT03987620 | phase3 | completed | 2019-06-07 | 2020-03-29 | Scynexis, Inc. | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis |
FDA applications (0)
No records yet.